MRT-201

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameMRT-201
Drug Alias NameGrB-Fc-4D5GranzymeB-Fc-scFv4D5Anti-Her2/neu targeted granzyme B immunotherapy (Mirata BioPharma)Granzyme B GrB-conjugated anti-human epidermal growth factor receptor 2 (Her2/neu) synthetic antibody (Mirata BioPharma)MRT-201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsBreast NeoplasmsAdenocarcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesClayton Foundation For Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesClayton Foundation For ResearchMirata BioPharma Llc
Active IndicationsN/A
Inactive IndicationsGastroesophageal Junction NeoplasmsBreast NeoplasmsAdenocarcinoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A